Prenatal genetic testing is under the remit of the National Health Service in
INTRODUCTION
Genetic disorders represent a signifi cant share of morbidity and mortality in pediatric population and are an important public health issue. Primary and secondary prevention genetic services are intended to prevent birth defects, genetic disorders, or disease before it occurs or before birth. New technologies, which could be utilized in prenatal genetic diagnosis, call for modifi cations and adaptations of the existing healthcare system.
In this work, we present development of the prenatal genetic service, the actual conditions and our recommendations for the future under the National Health Service in Slovenia.
TRADITIONAL APPROACH TO PRENATAL GENETIC DIAGNOSIS
Prenatal genetic diagnosis has been available in Slovenia since 1980 ( Figure 1 ). We started with karyotyping of amniotic fl uid, followed by chorionic villus sampling (CVS) in 1984. Chromosome analysis has been off ered to pregnant women of advanced age (37 years or above), women with abnormal ultrasound scan, positive screening test (Nuchal Translucency, Double or Triple Hormone Test), a live-born child or previous pregnancy with an identifi ed chromosome abnormality, or because one parent carries a chromosomal rearrangement. Diagnostic yield of classical karyotype is approximately 3%, excluding Down syndrome and other recognizable chromosomal syndromes (1) . Full chromosome analysis has long been regarded as the gold standard for prenatal testing.
Prenatal detection of single gene disorders has been available since 1997 for couples where one parent carries an autosomal dominant or X-linked disease or both parents are carriers of an autosomal recessive disorder. The basic molecular genetic tests, such as targeted allele-specific polymerase chain reaction (PCR)-based or restriction fragment analysis methodologies, Sanger sequencing or Southern blot were used to detect single gene disorders. In cases of unknown mutation, indirect approach by linkage analysis was used.
In 1998, we introduced the use of fl uorescent in situ hybridization (FISH) in the prenatal setting. FISH allowed for detection of new categories: (a) genomic or submicroscopic mutations; and (b) rapid fetal aneuploidy testing, later replaced by other methods (qfPCR or MLPA). Rapid fetal aneuploidy screening was followed by karyotype analysis.
Fluorescent in situ hybridization has fi lled the gap between molecular and cytogenetic diagnostic tests. In addition, FISH allows for analysis of metaphase chromosomes or interphase nuclei. FISH probes are used to identify microdeletions (2), subtelomeric rearrangements (3), and origin of marker chromosome (4), or for simple and complex chromosome rearrangements on metaphase chromosomes, whereas rapid fetal aneuploidy screening and evaluation of mosaicism can be done on interphase nuclei.
We have been using interphase FISH method for preimplantation genetic diagnosis (PGD) in which one or two blastomeres are biopsied from the early embryo for FISH analysis of known familial chromosome rearrangements, or for sex selection in X-linked monogenic disease (5, 6) .
GENOMIC TESTS IN PRENATAL GENETIC DIAGNOSIS
Now, we are facing genomic approaches. Array comparative genomic hybridization (aCGH) or molecular karyotyping can scan the entire genome to detect gains and losses of genetic material. aCGH was introduced into our routine in 2014, since the output is higher comparing to classical karyotyping, subtelomeric MLPA analysis or FISH. Prenatal aCGH is routinely used in the cases of ultrasound structural anomalies in the fetus, including nuchal translucency >3.5 mm, and in the case of prenatally detected chromosomal rearrangements using karyotyping (7, 8) . Clinically relevant genomic imbalances are reported in 4%-7% of fetuses with ultrasound detected structural anomalies (7, 9, 10) . Some laboratories completely switched over their prenatal invasive diagnosis to aCGH (11) . Apart from the fact that aCGH is more expensive compared to conventional karyotyping, there is another very important issue in prenatal diagnosis, i.e. how to deal with variants of unknown clinical signifi cance (VOUS), susceptibility loci (SL) for neurodevelopmental disorders and unexpected diagnoses.
In addition, aCGH has become a tool for discovering regions prone to genomic rearrangements (12) and for identifi cation of new deletion/duplication syndromes (13).
Moreover, Next Generation Sequencing (NGS) has radically changed the diagnosis of single gene disorders. It has shifted focus from the pre-NGS-test diff erential diagnostic mode to the post-NGS-test diagnostic assessment mode (14) . NGS allows for multi-gene analysis in a single investigation (15) . Since the implementation of NGS in the routine genetic testing, we have been increasingly harnessing its diagnostic potential to facilitate prenatal diagnosis. Whole human exome and genome sequencing based on NGS technology allows for comprehensive, rapid and accessible detection of a variety of mutational events in a patient with suspected genetic disease. Quality NGS service encompasses several steps, including proper pre-testing clinical assessment, massive parallel sequencing, and orthogonal validation with Sanger sequencing, data analysis and exhaustive interpretation. To ensure the timely and clinically valid diagnosis in the prenatal setting, we have been continuously optimizing each of these steps with the aim to reach 1-month referral-to-reporting time.
Recent reports indicate that exome sequencing facilitates prenatal genetic diagnosis (16) (17) (18) . Early studies performed in pregnancies with ultrasound structural fetal abnormalities have reported conclusive detection rate of 10% in karyotype-and microarray-negative cases (19, 20) . Targeted mutation testing
The comprehensive nature of exome and genome sequencing also carries the issue of reporting variants of unknown signifi cance, which are even more numerous than in microarray diagnosis. In our approach, we therefore limit the reporting of mutations only to those that are highly likely causative, which includes known pathogenic sequence variants and variants with certain impact (including non-sense and frameshift variants). Another challenge is the possibility of identifying unsolicited fi ndings in genes, which may manifest postnatally. We currently focus the analysis only on fi ndings pertinent to the referral diagnosis aiming to minimize the issue of identifying unwarranted incidental fi ndings. The complexity of such a comprehensive and complex diagnosis in the prenatal period thus requires specifi c and suffi ciently informative genetic counselling offered throughout the testing process.
The impact of NGS in a single gene landscape is analogous to aCGH in the cytogenetic domain. However, as NGS allows for detection of point mutations, small indels, CNVs and chromosome translocations (21) , it is anticipated that aCGH will soon be replaced.
Since 2013, noninvasive prenatal screening (NIPS) can be offered to women with high-risk pregnancy (22) . NIPS analyzes fetal DNA molecules, which are freed into the maternal circulation from the placental tissue. Professional Committee of the Slovenian Association of Medical Genetics currently recommends NIPS for pregnancies at a high risk of common trisomies, however, there is cumulative evidence of comparable NIPS test characteristics in low risk pregnancies. In Slovenia, NIPS is at the moment available on the patient self-pay basis. NIPS test has high specifi city (99%) and sensitivity (>99%) to detect fetal trisomy 21, 18, and 13, yet it has been shown to be slightly less specifi c and sensitive for sex chromosome aneuploidy detection. Positive predictive value for trisomy 21 is around 45.5% (23), which is 10 times better than the classical prenatal screening tests (nuchal translucency, combined screening test or triple/ quadruple screening test).
CURRENT PRACTICE AND FUTURE TRENDS
Rapid development of new technologies in medical genetics increases the costs of genetic service. There is a need for a diff erent approach, in which indication-matched tests would be used to maximize diagnostic yield at an acceptable cost.
Our prenatal genetic testing strategy specifi es pregnant women into high-risk and low-risk pregnancies (Figure 2 ).
High-risk pregnancy is defi ned as a positive screening test with a risk of 1:30 or more for chromosome abnormality, ultrasound detected fetal anomalies, high risk result of NIPS, or if one parent is carrier of a Robertsonian translocation involving chromosome 13 or 21, and, in addition, any other balanced chromosomal rearrangement or a single gene disorder. In these cases, rapid testing for fetal aneuploidy screening (qfPCR) is performed fi rst, followed by aCGH, when the qfPCR shows normal result. In the case of trisomy 21, 13 or suspected chromosome mosaicism detected by qfPCR, karyotyping of the prenatal sample is recommended to clarify the chromosome constitution (Figure 2 Previously, targeted mutation testing was performed if there were ultrasound-detected anomalies possibly associated with a specifi c single gene disorder. Because of the genetic heterogeneity of the disorders and limitations of prenatal ultrasound to defi ne fetal phenotype, the NGS approach will improve the performance. Since the introduction of NGS into our clinical routine, it has been demonstrated that the detection yield is far better than in other diagnostic tests currently in routine use. However, parents should be informed about the limitations of NGS and discuss it thoroughly at pre-test and post-test genetic counselling. A defi nitive genetic diagnosis would enable informed decisionmaking regarding continuation of the actual pregnancy and provide valuable information on the recurrence risk for future pregnancies.
On the other hand, low-risk pregnancies (advanced maternal age without any other screening test, previous pregnancy with chromosome aneuploidy and screening test with a risk higher than 1:300 and lower than 1:30) usually have normal qfPCR profi le and karyotype, placing substantial fi nancial burden upon healthcare budget, together with an increased risk of adverse pregnancy outcome because of the invasive procedure (CVS or amniocentesis). Similarly to some other European countries (24), we plan to off er rapid fetal aneuploidy testing as a stand-alone prenatal diagnostic test to pregnant women in low-risk group. Genetic counselling would be off ered to pregnant women in low-risk group, where they would have an opportunity to discuss the advantages and limitations of the tests and would be off ered a choice; they could opt between qfPCR and full chromosome karyotyping. In the case of abnormal karyotype, such as marker chromosome or unbalanced chromosome rearrangement, aCGH would be done to determine more accurately genomic gains or losses ( Figure 2 ).
We are aware that rapid fetal aneuploidy testing cannot substitute full karyotype, since it gives information on numerical aberrations of chromosome 13, 18, 21 and sex chromosomes only, therefore, eventual reciprocal translocation, supernumerary marker chromosome or other rarer chromosome fi ndings might be missed. However, in our experience, unbalanced chromosome rearrangements that could be detected by routine chromosome analysis are usually accompanied by developmental abnormalities of the fetus and would be detected by ultrasound examination of fetal morphology. It has been shown that rapid delivery of results using qfPCR as a stand-alone test for pregnancies without ultrasound anomalies reduces parental anxiety (24) .
At the Clinical Institute of Medical Genetics, among other genetic diagnostic procedures, PGD (pre-implantation genetic diagnosis) is available within the remit of the Health Service (no out of pocket expenses) for couples at a high risk of genetically disadvantaged off spring, either for chromosomal unbalanced rearrangement or single gene disorder.
CONCLUSION
We are witnessing rapid development of modern methodologies. However, technological advances are not always accompanied by the resources required to meet laboratory and medical needs. The challenge therefore is how to off er the best modern, rapid and appropriate medical services at an acceptable cost. In Slovenia, we have already introduced modern techniques into routine clinical practice. We are developing a strategy in the prenatal diagnostic setting to ensure best diagnostic yield with a combination of genetic tests at an aff ordable cost.
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